Autologous hematopoietic stem cell transplantation for Behçet's Disease: a retrospective survey of patients treated in Europe, on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
Lim, Y. J.
Ma, D. D.
Snowden, J. A.
AffiliationCHU de Poitiers, Service de Médecine Interne et Maladies Infectieuses, Poitiers, France
MetadataShow full item record
AbstractBackground: Behçet's Disease (BD) is an autoimmune disease mostly presenting with recurrent oral and genital aphthosis, and uveitis. Patients are rarely refractory to immunosuppressive treatments. Autologous hematopoietic stem cell transplantation (aHSCT) is a standard of care in other autoimmune diseases. Some patients with BD have been treated with aHSCT based on compassionate use. Objectives: Evaluate the outcome of aHSCT in adult patients with BD treated in member centers of the European Society for Blood and Marrow Transplantation (EBMT). Methods: Adults who received aHSCT primarily for BD were identified retrospectively in the EBMT registry and/or in published literature. Data were extracted from either medical records of the patient or from publications. Results: Eight out of 9 cases reported to the registry and extracted data of 2 further patients from literature were analyzed. Four were female, median age at onset of BD was 24y (range 9-50). Median age at aHSCT was 32y (27-51). Patients had received median 4 (2-11) previous lines of therapy (89% corticosteroids, 50% methotrexate, anti-TNFα therapy or cyclophosphamide). All patients had active disease before mobilization. Conditioning regimen was heterogeneous. Median follow-up was 48 months (range 6-240). No treatment-related mortality was reported. This procedure induced complete remission (CR) in 80%, partial remission in 10% and lack of response in 10% of the patients. Relapse rate was 30% (2 relapses in patients in CR and 1 relapse in the patient in PR) with panuveitis (n=1), aphthosis (n=2) and arthralgia (n=1). Six patients were in CR. No late complications were reported. Conclusion: aHSCT has an acceptable safety profile and represents a feasible and relatively effective procedure in severe and conventional treatment-resistant cases of BD and has the potential to stabilize BD in patients with life-threatening involvements.
CitationPuyade M, Patel A, Lim YJ, Blank N, Badoglio M, Gualandi F, et al. Autologous Hematopoietic Stem Cell Transplantation for Behçet’s Disease: A Retrospective Survey of Patients Treated in Europe, on Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. Front Immunol. 2021 May 6;12.
JournalFrontiers in Immunology
- Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in refractory Takayasu arteritis: a retrospective multicenter case-series from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT).
- Authors: Laurent C, Marjanovic Z, Ricard L, Henes J, Dulery R, Badoglio M, Farge D, Snowden JA, Moraes D, Dias J, Mohty M, Soussan M, Fain O, Arnold R, Alexander T, Oliveira MC, Mekinian A
- Issue date: 2020 Nov
- Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation.
- Authors: Brierley CK, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J, Onida F, Cassinotti A, Satsangi J, Kazmi M, López-Sanromán A, Schmidt C, Farge D, Travis SPL, Hawkey CJ, Snowden JA, European Society for Blood and Marrow Transplantation [EBMT] Autoimmune Diseases Working Party [ADWP].
- Issue date: 2018 Aug 29
- Bone marrow transplantation for Behçet's disease: a case report and systematic review of the literature.
- Authors: Soysal T, Salihoğlu A, Esatoğlu SN, Gültürk E, Eşkazan AE, Hatemi G, Hatemi I, Öngören Aydın Ş, Erzin YZ, Başlar Z, Tüzüner N, Ferhanoğlu B, Çelik AF
- Issue date: 2014 Jun
- [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
- Authors: Shi Y, Pan F, Han X
- Issue date: 1999 Dec
- Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis.
- Authors: Helbig G, Koclęga A, Woźniczka K, Kopera M, Kyrcz-Krzemień S
- Issue date: 2018 Jul